Table 2

Baseline patient demographic data and disease characteristics. Data represent mean (SD) unless stated otherwise.

CharacteristicPlacebo, n = 153Fostamatinib 150 mg qd, n = 152Fostamatinib 100 mg bid, n = 152
Age, yrs52.4 (13.2)52.6 (12.3)52.5 (13.0)
Female, n (%)131 (85.6)128 (84.2)131 (86.2)
Race or ethnic group, n (%)
 White71 (46.4)75 (49.3)58 (38.2)
 Hispanic75 (49.0)74 (48.7)88 (57.9)
Disease duration, yrs9.5 (8.7)9.7 (9.1)8.4 (8.2)
No. swollen joints12.2 (4.9)12.3 (5.4)11.8 (5.0)
Score on DAS286.2 (0.8)6.1 (0.9)6.2 (0.9)
Positive for rheumatoid factor, %85.081.189.1
Treatment with prednisone ≤ 10 mg/day, %61.456.661.2
Previous therapy with biologic response modifiers, %14.415.814.5
  • bid: twice daily; qd: once daily; DAS28: 28-joint Disease Activity Score.